^
    Back
    Association details:
    Biomarker:EPHB4 expression
    Cancer:Pancreatic Cancer
    Drug:gemcitabine (DNA synthesis inhibitor) +
    albumin-bound paclitaxel (Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    A phase Ib study of sEphB4-HSA combined with first-line chemotherapy in patients (pts) with advanced pancreatic (PC) and biliary cancers (BC).

    Published date:
    05/13/2020
    Excerpt:
    In the PC cohort, there was an association between EphB4 expression and objective response (p = 0.009).
    DOI:
    10.1200/JCO.2020.38.15_suppl.4640
    Trial ID:
    NCT02495896